What Edesa Biotech does

Edesa Biotech is a clinical-stage biopharmaceutical company founded in 2015 by Dr. Par Nijhawan and headquartered in Markham, Ontario, Canada. The company went public in June 2019 via a reverse merger with Stellar Biotechnologies and trades on Nasdaq under the ticker EDSA. Edesa is incorporated under the laws of British Columbia and operates through a principal R&D subsidiary (Edesa Biotech Research) and a U.S. subsidiary in Southern California.

The company develops a portfolio of host-directed therapeutics—primarily monoclonal antibodies and enzyme inhibitors—targeting immune dysregulation pathways implicated in dermatological, respiratory, and inflammatory diseases. Its core pipeline consists of three drug candidates: paridiprubart (EB05), a first-in-class anti-TLR4 monoclonal antibody for Acute Respiratory Distress Syndrome (ARDS) with additional development in acute kidney injury, sepsis, and pneumonia; EB06, an anti-CXCL10 monoclonal antibody for moderate-to-severe vitiligo; and EB01 (1.0% daniluromer cream), a Phase 3-ready topical sPLA2 inhibitor for allergic contact dermatitis. Paridiprubart demonstrated a 27% relative reduction in 28-day mortality across 278 randomized ARDS patients in a Phase 3 study, and the candidate has been selected by U.S. BARDA for a government-funded Phase 2 platform study.

Edesa is pre-revenue with no commercialized products, generating no product sales as of fiscal 2025. The company funds operations through periodic private placements (approximately $28.5 million raised across 2022-2026 PIPEs) and Canadian government grants (cumulative C$37 million from the Strategic Innovation Fund). Its customer base is essentially limited to capital providers, with a near-term revenue model dependent on eventual regulatory approval and pharmaceutical distribution through wholesalers, specialty pharmacies, and hospital purchasing systems, potentially in partnership with strategic collaborators for late-stage commercialization.

Name

Edesa Biotech

Legal name

Edesa Biotech Inc.

Website

https://edesabiotech.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed monoclonal antibody and topical therapeutics for acute respiratory distress syndrome, vitiligo, and allergic contact dermatitis. Pre-revenue and Nasdaq-listed under EDSA, the company serves patients with high-unmet-need inflammatory and immune-related diseases.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals / Host-Directed Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Host-directed therapeutics
• Monoclonal antibody development
• Inflammatory disease treatment
• Clinical-stage biopharmaceuticals
• Dermatology therapeutics

Headquarters

HQ city

Markham

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage company. Once drug candidates receive regulatory approval, the company plans to commercialize products through traditional pharmaceutical distribution channels. Current products in development include paridiprubart for ARDS, EB06 for vitiligo, and EB01 for allergic contact dermatitis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Edesa Biotech is a clinical-stage biopharmaceutical company developing first-in-class host-directed therapeutics—monoclonal antibodies and topical enzyme inhibitors—for inflammatory and immune-related diseases. The company is advancing three drug candidates: paridiprubart (EB05), an anti-TLR4 monoclonal antibody for Acute Respiratory Distress Syndrome (ARDS); EB06, an anti-CXCL10 monoclonal antibody for moderate-to-severe vitiligo; and EB01, a topical sPLA2 inhibitor cream for allergic contact dermatitis.

Product overview

Edesa Biotech is a clinical-stage biopharmaceutical company developing a portfolio of monoclonal antibody and topical anti-inflammatory drug candidates for immuno-inflammatory diseases. The core pipeline consists of: Paridiprubart (EB05), a first-in-class anti-TLR4 antibody for respiratory conditions including ARDS and acute kidney injury; EB06, an anti-CXCL10 antibody for vitiligo; and EB01 (daniluromer cream), a Phase 3-ready sPLA2 inhibitor for allergic contact dermatitis. These candidates are developed through the company's Host Directed Therapeutics platform, which focuses on modulating the body's own immune response rather than directly targeting pathogens.

Differentiator

Problem solved

Functional benefit

Products and services

• Paridiprubart (EB05) A first-in-class anti-TLR4 monoclonal antibody being developed as a Host-Directed Therapeutic for Acute Respiratory Distress Syndrome (ARDS) and acute kidney injury (AKI). The drug modulates the body's immune response to treat respiratory conditions, with additional development for sepsis and pneumonia. Demonstrated 27% relative reduction in 28-day mortality across 278 Phase 3 patients (24% vs 33% placebo, p<0.001).
• EB06 An anti-CXCL10 monoclonal antibody in development for moderate-to-severe non-segmental vitiligo, a common autoimmune disorder causing skin depigmentation. The drug targets the CXCL10 chemokine which plays a key role in the disease pathophysiology, with neutralization of CXCL10 demonstrated to both prevent and reverse depigmentation in animal models.
• EB01 (1.0% Daniluromer Cream) A Phase 3-ready topical secretory phospholipase 2 (sPLA2) inhibitor cream being developed for allergic contact dermatitis, a common occupational skin condition. The drug targets sPLA2 at the inception of inflammation to provide anti-inflammatory effects without steroid-related safety concerns, addressing a common occupational health condition with limited non-steroidal treatment options.

Quantifiable outcome

• 27% relative reduction in 28-day mortality (24% vs 33% placebo, p<0.001) across 278 randomized ARDS patients
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• JSS Medical ResearchcoreImplementation/ SI/ Consulting Partner · 26 March 2026JSS Medical Research serves as the contract research organization (CRO) for Edesa's clinical trials, including the Phase 2 vitiligo study for EB06 and Phase 3 studies for paridiprubart. The CRO conducted data analyses and manages international clinical trial operations.

Scale indicators16 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Faron Pharmaceuticals: Clinical-stage biopharma developing interferon beta-1a (trafermin) for ARDS; directly comparable to Edesa as a small-cap, clinical-stage host-directed therapeutic developer in the same ARDS indication.
• InMed Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-based therapeutics for inflammatory and dermatological diseases; comparable small-cap clinical pipeline model with dermatology/inflammation overlap.
• Mesoblast: Late-stage cell therapy company developing remestemcel-L for ARDS and inflammatory conditions; directly comparable in pursuing novel immune-modulating approaches to ARDS.
• BioLineRx: Clinical-stage biopharmaceutical company developing immunomodulatory therapeutics; comparable small-cap clinical pipeline model focused on immune-related diseases.
• RedHill Biopharma: Specialty biopharmaceutical company developing therapeutics for gastrointestinal and inflammatory diseases; similar clinical-to-commercial-stage profile and immunology focus.

Emerging players

• Pluristem Therapeutics: Clinical-stage cell therapy company developing PLX cells for inflammatory and pulmonary conditions including ARDS; overlapping host-directed therapeutic strategy.
• Athersys: Clinical-stage cell therapy company that advanced MultiStem for ARDS; directly comparable in pursuing novel modalities for respiratory inflammation, though now restructured.
• Compass Pathways: Clinical-stage biotechnology company developing novel therapies; comparable small-cap clinical-stage biotech with platform-based therapeutic approach, though focused on different therapeutic area.

Broad incumbents

• Incyte Corporation: Established biopharmaceutical company with Opzelura (ruxolitinib cream), an approved treatment for vitiligo; directly competitive in EB06's target indication and a benchmark for vitiligo commercial opportunity.
• Pfizer: Large pharmaceutical company with established immunology and dermatology franchises (e.g., JAK inhibitor programs for vitiligo); broad incumbent with overlapping indications and far greater commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/edesa-biotech
• Xx.com/edesabiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds11 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edesa Biotech